LY4086040

LY4086040 is an investigational long-acting amylin receptor agonist developed by Eli Lilly and Company for the treatment of obesity. As an analog of the naturally occurring peptide hormone amylin, it functions by binding to and activating amylin receptors in the central nervous system, particularly in the area postrema of the hindbrain, to promote satiety and reduce caloric intake. Amylin is co-secreted with insulin from pancreatic beta cells and plays a critical role in glycemic control and appetite regulation. By mimicking these effects with a prolonged half-life, LY4086040 aims to provide a potent weight-loss effect, potentially as a monotherapy or in combination with other incretin-based therapies such as GLP-1 or GIP receptor agonists. It is currently undergoing Phase 1 clinical evaluation to assess its safety, tolerability, and pharmacokinetics in healthy individuals and participants with obesity.